Rituximab's Effectiveness in Treating Membranous Nephropathy
Author Information
Author(s): Li Zhuo, Zhao Tingting, Zhang Shasha, Huang Jing, Wang Honggang, Sun Yujiao, Wang Rong, Chen Bing
Primary Institution: Shandong Provincial Hospital Affiliated to Shandong First Medical University
Hypothesis
Can rituximab effectively treat patients with primary membranous nephropathy who are dependent on calcineurin inhibitors?
Conclusion
Rituximab effectively achieves complete clinical and immunological remission in patients with primary membranous nephropathy who are dependent on or partially responsive to long-term calcineurin inhibitor therapy.
Supporting Evidence
- All drug-dependent patients overcame calcineurin inhibitor dependency after 12 months of rituximab treatment.
- The complete remission rate in the drug-dependent group increased from 10% to 70% after treatment.
- Complete immunological remission rates rose from 35% to 90% in the drug-dependent group.
Takeaway
This study shows that rituximab can help patients with a kidney disease called membranous nephropathy get better and stop needing other medications that can be harmful.
Methodology
The study involved 36 patients divided into two groups, receiving rituximab therapy while tapering off calcineurin inhibitors, with outcomes assessed after 12 months.
Limitations
The study is retrospective and conducted at a single center with a small sample size.
Participant Demographics
All participants were adults diagnosed with primary membranous nephropathy.
Statistical Information
P-Value
0.016
Statistical Significance
p=0.016
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website